TY - JOUR

T1 - Filling the gaps in generalized pustular psoriasis

T2 - Role of IL-36R antibodies

AU - Nielsen, V. W.

AU - Thomsen, S. F.

N1 - Publisher Copyright: © 2021 Clarivate.

PY - 2021/12

Y1 - 2021/12

N2 - Generalized pustular psoriasis (GPP) is a rare skin disorder that presents with flares of extensive sterile pustules. No GPP-specific treatment has been approved in the U.S. or Europe, and the lack of universal guidelines complicates the treatment of this debilitating disease. Recently, the pathophysiology of GPP has been attributed to overactivation of the interleukin-36 (IL-36) signaling pathway, due to loss-of-function mutations uncovered in the gene encoding the IL-36 receptor antagonist. The IL-36 receptor has therefore become a promising target for therapeutic intervention, with early studies of anti-IL-36R treatment, namely spesolimab and imsidolimab, demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symptoms. Both treatments were well tolerated with no serious adverse events reported, making anti-IL-36R treatment a promising addition to the sparse therapeutic options currently available.

AB - Generalized pustular psoriasis (GPP) is a rare skin disorder that presents with flares of extensive sterile pustules. No GPP-specific treatment has been approved in the U.S. or Europe, and the lack of universal guidelines complicates the treatment of this debilitating disease. Recently, the pathophysiology of GPP has been attributed to overactivation of the interleukin-36 (IL-36) signaling pathway, due to loss-of-function mutations uncovered in the gene encoding the IL-36 receptor antagonist. The IL-36 receptor has therefore become a promising target for therapeutic intervention, with early studies of anti-IL-36R treatment, namely spesolimab and imsidolimab, demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symptoms. Both treatments were well tolerated with no serious adverse events reported, making anti-IL-36R treatment a promising addition to the sparse therapeutic options currently available.

KW - ANB-019

KW - Generalized pustular psoriasis

KW - IL-36 receptor antibody

KW - IL36RN

KW - Imsidolimab

KW - Spesolimab

U2 - 10.1358/dof.2021.46.12.3331003

DO - 10.1358/dof.2021.46.12.3331003

M3 - Journal article

AN - SCOPUS:85122241625

VL - 46

SP - 995

EP - 1002

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 12

ER -